AMENDMENTS TO THE SPECIFICATION

Deletions are strikethrough and additions are underlined.

Abstract

Amend Abstract [a clean version (Substitute Abstract) of the abstract on a single page is submitted with this response]

A cancer gene therapeutic drug of the present invention disclosure comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to an administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration so as to make the oncolytic virus act on a tumor cell within the living body. For example, A549 cell can be used as the carrier cell, Na non-proliferative adenovirus inactivated by UV irradiation can be used as the virus for immunological treatment, and a proliferative adenovirus having a tumor-specific promoter can be used as the oncolytic virus, for example.

Specification

The Specification has been amended to correct errors in English grammar, style, and clarity. A "Marked-Up Version" is submitted showing all the amendments to the Specification. A "Substitute Specification", which is a clean version with all the amendments made to the text, is submitted with this response.